Preventing Adverse Drug Events With PatientSite
- A drug safety module called MedCheck was developed for PatientSite. This allows
physicians to query patients automatically 10 days after they receive a new
prescription asking them questions about their new prescription. In this study new
enhancements will be tested.
- Participants will be assigned at random to the intervention group or control group.
The intervention group will receive a single electronic PatientSite message asking them
questions about the new prescription which is then forwarded to their physician. The
control group will receive a generic message about medication safety.
- To identify adverse drug events, a telephone survey and medical record review will be
conducted of patients in the intervention group and controls.
- This study will run for 12 months.
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
To prevent adverse drug events with PatientSite.
Saul N Weingart, MD, PhD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|